XML 137 R93.htm IDEA: XBRL DOCUMENT v3.22.4
Principal alliances -Collaboration agreements on human therapeutic antibodies (Details)
€ in Millions, $ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 01, 2020
Jul. 01, 2015
agreement
Nov. 30, 2007
agreement
Mar. 31, 2022
Dec. 31, 2022
Rate
Dec. 31, 2022
EUR (€)
bond
Rate
Dec. 31, 2022
USD ($)
bond
Rate
Dec. 31, 2021
EUR (€)
Dec. 31, 2020
EUR (€)
Dec. 31, 2015
Disclosure of detailed information about Principal Alliances [Line Items]                    
Net sales | €           € 42,997   € 37,761 € 36,041 [1]  
US                    
Disclosure of detailed information about Principal Alliances [Line Items]                    
Net sales | €           € 18,275   € 14,385 € 13,465  
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement                    
Disclosure of detailed information about Principal Alliances [Line Items]                    
Number of agreements signed | agreement     2              
Phase III costs, responsibility percentage           80.00% 80.00%      
Phase III costs, responsibility percentage for Regeneron           20.00% 20.00%      
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)       10.00% 20.00%          
Percentage of cumulative development costs reimbursed           50.00% 50.00%      
Period before scheduled launch date           24 months 24 months      
Number of payments | bond           2 2      
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Sales of antibodies, first achievement                    
Disclosure of detailed information about Principal Alliances [Line Items]                    
Payment related to attainment of goal             $ 50      
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Sales of antibodies, first achievement | Antibodies                    
Disclosure of detailed information about Principal Alliances [Line Items]                    
Net sales             2,000      
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Sales of antibodies, second achievement                    
Disclosure of detailed information about Principal Alliances [Line Items]                    
Payment related to attainment of goal             50      
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Sales of antibodies, second achievement | Antibodies                    
Disclosure of detailed information about Principal Alliances [Line Items]                    
Net sales             $ 2,500      
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Prior agreement                    
Disclosure of detailed information about Principal Alliances [Line Items]                    
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) | Rate         10.00% 10.00% 10.00%      
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | New agreement                    
Disclosure of detailed information about Principal Alliances [Line Items]                    
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) | Rate           20.00% 20.00%      
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Sales Of Antibodies, Third Achievement                    
Disclosure of detailed information about Principal Alliances [Line Items]                    
Payment related to attainment of goal             $ 50      
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Sales Of Antibodies, Third Achievement | Antibodies                    
Disclosure of detailed information about Principal Alliances [Line Items]                    
Net sales             $ 3,000      
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | US                    
Disclosure of detailed information about Principal Alliances [Line Items]                    
Percentage of profits and losses arising from commercial operations           50.00% 50.00%      
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Outside the United States                    
Disclosure of detailed information about Principal Alliances [Line Items]                    
Percentage of losses arising from commercial operations           55.00% 55.00%      
Royalty expense, percentage (percentage) 5.00%                  
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Outside the United States | Bottom of range                    
Disclosure of detailed information about Principal Alliances [Line Items]                    
Percentage of profits arising from commercial operations           55.00% 55.00%      
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement | Outside the United States | Top of range                    
Disclosure of detailed information about Principal Alliances [Line Items]                    
Percentage of profits arising from commercial operations           65.00% 65.00%      
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement                    
Disclosure of detailed information about Principal Alliances [Line Items]                    
Number of agreements signed | agreement   2                
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent)                   10.00%
Percentage of cumulative development costs reimbursed                   50.00%
[1] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.